Abstract PS4-08-11: Standardized Definitions for Efficacy End Points (STEEP, STEEP2) in the CCTG MA.32 randomized breast cancer trial of metformin versus placebo: Implications of the type of recurrence and new non-breast cancer primary on outcome assessment